NCT00384956View on ClinicalTrials.gov

A Phase II Study of Intravenous Azacitidine Alone in Patients With Myelodysplastic Syndromes

PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

August 31, 2006

Primary Completion Date

August 31, 2008

Study Completion Date

March 31, 2010

Conditions
Myelodysplastic Syndromes
Interventions
DRUG

Azacitidine

Trial Locations (1)

63110

Washington University School of Medicine, St Louis

All Listed Sponsors
lead

Washington University School of Medicine

OTHER

NCT00384956 - A Phase II Study of Intravenous Azacitidine Alone in Patients With Myelodysplastic Syndromes | Biotech Hunter | Biotech Hunter